TTrialPathMatch Me to Trials
← Back to trials
RecruitingHypertrophic Cardiomyopathy

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

Eligible age

18–75 yrs

Accepts

All genders

Locations

8 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic hypertrophic cardiomyopathy (HCM) caused by mutations in the MYBPC3 gene.

Sponsor: Tenaya Therapeutics

You may qualify if…

  • ✓ MYBPC3 mutation
  • ✓ Hypertrophic Cardiomyopathy (obstructive and nonobstructive)
  • ✓ Left Ventricular Ejection Fraction ≥45%
  • ✓ NYHA Functional Class II or III symptoms
  • ✓ NT-proBNP ≥160pg/ml

You may not qualify if…

  • ✕ High AAV9 neutralizing antibody titer

Where it's recruiting

California

La Jolla · San Francisco

Georgia

Atlanta

Minnesota

Rochester

Ohio

Cincinnati · Cleveland

Oregon

Portland

Pennsylvania

Philadelphia

Texas

Houston

Source: ClinicalTrials.gov · NCT05836259 · last updated 2026-03-19